BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-3095 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-3095\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07613866-11104@assetmemo.bio
DTSTAMP:20261121T005643Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-3095: Phase 2 readout est. (NCT07613866)
DESCRIPTION:HRS-3095\, phase 2\, Chronic Spontaneous Urticaria.\nStudy: A C
 linical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria\n
 Estimated primary completion: December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hrs-3095#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07613866
URL:https://assetmemo.bio/drug/hrs-3095#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
